Cellular targets of gefitinib
D Brehmer, Z Greff, K Godl, S Blencke, A Kurtenbach… - Cancer research, 2005 - AACR
D Brehmer, Z Greff, K Godl, S Blencke, A Kurtenbach, M Weber, S Müller, B Klebl, M Cotten…
Cancer research, 2005•AACRTargeted inhibition of protein kinases with small molecule drugs has evolved into a viable
approach for anticancer therapy. However, the true selectivity of these therapeutic agents
has remained unclear. Here, we used a proteomic method to profile the cellular targets of
the clinical epidermal growth factor receptor kinase inhibitor gefitinib. Our data suggest
alternative cellular modes of action for gefitinib and provide rationales for the development
of related drugs.
approach for anticancer therapy. However, the true selectivity of these therapeutic agents
has remained unclear. Here, we used a proteomic method to profile the cellular targets of
the clinical epidermal growth factor receptor kinase inhibitor gefitinib. Our data suggest
alternative cellular modes of action for gefitinib and provide rationales for the development
of related drugs.
Abstract
Targeted inhibition of protein kinases with small molecule drugs has evolved into a viable approach for anticancer therapy. However, the true selectivity of these therapeutic agents has remained unclear. Here, we used a proteomic method to profile the cellular targets of the clinical epidermal growth factor receptor kinase inhibitor gefitinib. Our data suggest alternative cellular modes of action for gefitinib and provide rationales for the development of related drugs.
AACR